Novo Nordisk is temporarily reducing the supply of Wegovy (semaglutide), a GLP-1 receptor agonist approved in June 2021 as a once-weekly self-injection for weight control in people with obesity, due to production problems at one of the company’s contract manufacturing sites. Semaglutide had previously been approved for type 2 diabetes under the brand name Ozempic.   Production problems encountered in August 2022 led to a growing gap between the burgeoning demand for Wegovy and Novo Nordisk’s s...